share_log

TransMedics | 10-Q: Q3 2024 Earnings Report

TransMedics | 10-Q: Q3 2024 Earnings Report

TransMedics | 10-Q：2024财年三季报
美股SEC公告 ·  2024/10/29 13:24

Moomoo AI 已提取核心信息

TransMedics Group reported strong Q3 2024 financial results with total revenue reaching $108.8 million, up 64% year-over-year, driven by significant growth in both product and service revenue. Net income was $4.2 million compared to a net loss of $25.4 million in Q3 2023. Product revenue grew to $65.9 million while service revenue from the National OCS Program (NOP) increased to $42.9 million.The company's U.S. OCS transplant revenue surged to $104.9 million, up from $59.7 million last year, with particularly strong growth in OCS Liver and Heart segments. Gross margin was 56%, with product gross margin at 80% and service gross margin at 19%. Operating expenses increased to $56.9 million as the company continued investing in commercial expansion and R&D.TransMedics maintained a strong balance sheet with $330.1 million in cash as of September 30, 2024. The company expanded its logistics capabilities through aircraft acquisitions and pilot hiring to support NOP growth. Management indicated continued focus on scaling manufacturing operations, developing next-generation OCS technology, and growing the commercial team to drive further market penetration.
TransMedics Group reported strong Q3 2024 financial results with total revenue reaching $108.8 million, up 64% year-over-year, driven by significant growth in both product and service revenue. Net income was $4.2 million compared to a net loss of $25.4 million in Q3 2023. Product revenue grew to $65.9 million while service revenue from the National OCS Program (NOP) increased to $42.9 million.The company's U.S. OCS transplant revenue surged to $104.9 million, up from $59.7 million last year, with particularly strong growth in OCS Liver and Heart segments. Gross margin was 56%, with product gross margin at 80% and service gross margin at 19%. Operating expenses increased to $56.9 million as the company continued investing in commercial expansion and R&D.TransMedics maintained a strong balance sheet with $330.1 million in cash as of September 30, 2024. The company expanded its logistics capabilities through aircraft acquisitions and pilot hiring to support NOP growth. Management indicated continued focus on scaling manufacturing operations, developing next-generation OCS technology, and growing the commercial team to drive further market penetration.
TransMedics集团公布了2024年第三季度强劲的财务业绩，总营业收入达到10880万美元，同比增长64%，这得益于产品和服务营业收入的显著增长。净利润为420万美元，而2023年第三季度的净亏损为2540万美元。产品营业收入增长至6590万美元，而国家OCS项目（NOP）的服务营业收入则增加至4290万美元。公司美国OCS移植营业收入猛增至10490万美元，较去年的5970万美元大幅增长，特别是在OCS肝脏和心脏领域表现强劲。毛利率为56%，其中产品毛利率为80%，服务毛利率为19%。营业费用增加至5690万美元，因为公司继续投资于商业扩张和研发。截至2024年9月30日，TransMedics保持了强劲的资产负债表，持有现金33010万美元。公司通过收购飞机和雇用飞行员增强其物流能力，以支持NOP的增长。管理层表示将继续注重扩大制造业-半导体运营，开发下一代OCS科技，并扩大商业团队以推动进一步的市场渗透。
TransMedics集团公布了2024年第三季度强劲的财务业绩，总营业收入达到10880万美元，同比增长64%，这得益于产品和服务营业收入的显著增长。净利润为420万美元，而2023年第三季度的净亏损为2540万美元。产品营业收入增长至6590万美元，而国家OCS项目（NOP）的服务营业收入则增加至4290万美元。公司美国OCS移植营业收入猛增至10490万美元，较去年的5970万美元大幅增长，特别是在OCS肝脏和心脏领域表现强劲。毛利率为56%，其中产品毛利率为80%，服务毛利率为19%。营业费用增加至5690万美元，因为公司继续投资于商业扩张和研发。截至2024年9月30日，TransMedics保持了强劲的资产负债表，持有现金33010万美元。公司通过收购飞机和雇用飞行员增强其物流能力，以支持NOP的增长。管理层表示将继续注重扩大制造业-半导体运营，开发下一代OCS科技，并扩大商业团队以推动进一步的市场渗透。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Pacific Biosciences of California
    PACB
    -- 1.850
    Avita Medical
    RCEL
    -- 10.570
    PAVmed
    PAVM
    -- 0.7900
    古特拉
    CUTR
    -- 0.481
    Lifeward
    LFWD
    -- 2.185
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    多家机构看多！中国资产将全面重估：你会如何布局？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家机构唱好中国资产。 🎙️讨论： 1. Deepseek引爆中国资产上涨，后市你怎么看？ 2. 多家中国企业1月表现提升，你更看好谁？ 展开
    中国的资产重估引发了讨论：mooer们在买什么？